Loss of Ferroptosis-suppressors Accelerates Breast Cancer Recurrence by Promoting Dormancy Exit
The deletion of certain ferroptosis-suppressing genes in dormant breast cancer cells may accelerate tumor recurrence, raising questions about the effectiveness of targeting ferroptosis in treatment.
Where it sits
this study against the rest of the glutathione (gsh) corpusSummary and findings
This study examined the role of ferroptosis regulators in breast cancer recurrence using a mouse model. Deletion of PNPLA2, GOT1, or GPX4 accelerated tumor recurrence, suggesting a link between these genes and dormant tumor cell reactivation. The research also identified an elevated ratio of reduced to oxidized glutathione in dormant cells, which may contribute to their resistance to ferroptosis.
Abstract
Breast cancer mortality is principally due to recurrent metastatic disease that may commonly emerge from a state of dormant minimal residual disease following definitive treatment of a primary tumor. Our genomic analysis of paired primary and metastatic breast cancers arising in the same patients resulted in the identification of the ferroptosis pathway as being preferentially mutated in metastases. An in vivo CRISPR-Cas9 screen of known ferroptosis regulators in mice identified guides targeting PNPLA2 , GOT1 , and GPX4 as being selected for in late dormancy and recurrence, which was surprising given the ferroptosis- suppressing functions ascribed to these proteins. However, recurrence-free survival assays in mice confirmed that deletion of PNPLA2 , GOT1 , or GPX4 accelerated tumor recurrence in mice and provided further evidence that this acceleration was attributable to an increased probability that dormant tumor cells deleted for these genes would reenter the cell cycle. Using a model of therapy-associated breast cancer dormancy, we also found that dormant cancer cells were markedly resistant to ferroptosis-inducing stimuli, including erastin and RSL3. Moreover, dormant tumor cells lacking PNPLA2 , GOT1 , or GPX4 displayed enhanced ferroptosis resistance compared to wildtype cells. Probing this ferroptosis-resistant state revealed that the ratio of reduced to oxidized glutathione was elevated in dormant cells. Moreover, deletion of PNPLA2 , GOT1 , or GPX4 further increased this ratio in dormant cells, suggesting that an increased ratio of reduced to oxidized glutathione may contribute to ferroptosis resistance in dormant tumor cells, especially those lacking these genes, potentially by rendering them more capable of handling lipid oxidative stress. Consistent with our findings in mice, analysis of human breast cancer patient data revealed that patients with copy number loss of PNPLA2 , GOT1 , or GPX4 exhibited worse recurrence-free and overall survival. Together, our study implicates three genes in the process of recurrence from dormant tumor cells and identifies a unique metabolic feature of the dormant tumor cell state. The surprising resistance to ferroptosis inducers exhibited by dormant tumor cells, as well as counterintuitive effects of deleting ferroptosis-suppressing genes on tumor recurrence following dormancy, raise questions regarding the utility of targeting ferroptosis in cancer that merit further study.
Background
This paper addresses the mechanisms underlying breast cancer recurrence, particularly focusing on dormant minimal residual disease. Previous research has indicated that dormant tumor cells can evade treatment and later re-emerge as metastatic disease. Understanding the genetic and metabolic factors influencing this process is crucial for developing effective therapeutic strategies.
Methods
The study employed an in vivo CRISPR-Cas9 screen to identify ferroptosis regulators in mice. Specific genes, including PNPLA2, GOT1, and GPX4, were targeted, and their effects on tumor recurrence were assessed. The study also analyzed the ratio of reduced to oxidized glutathione in dormant tumor cells.
Results
The deletion of PNPLA2, GOT1, or GPX4 was found to accelerate tumor recurrence in mice. Dormant tumor cells lacking these genes exhibited enhanced resistance to ferroptosis-inducing stimuli. The study also reported an elevated ratio of reduced to oxidized glutathione in dormant cells, which was further increased by gene deletion.
Interpretation
These findings suggest a complex relationship between ferroptosis regulators and tumor recurrence, which contrasts with previous assumptions about their roles. While the statistical significance of the results is noted, the clinical relevance remains uncertain, particularly given the small sample size and reliance on animal models. Further research is needed to explore the implications for targeting ferroptosis in cancer treatment.
Key findings
- Deletion of PNPLA2, GOT1, or GPX4 accelerated tumor recurrence in mice.
- Dormant tumor cells lacking PNPLA2, GOT1, or GPX4 displayed enhanced ferroptosis resistance compared to wildtype cells.
- The ratio of reduced to oxidized glutathione was elevated in dormant cells.
- Deletion of PNPLA2, GOT1, or GPX4 further increased the ratio of reduced to oxidized glutathione in dormant cells.
- Patients with copy number loss of PNPLA2, GOT1, or GPX4 exhibited worse recurrence-free and overall survival.
Limitations
- Based on mouse models, which may not fully translate to human biology.
- Preliminary findings require further validation in clinical settings.
- Small sample size in the context of human data analysis.
- No long-term follow-up reported to assess durability of findings.